Neuproscan
Neuproscan is an AI platform designed to predict the onset of Dementia from MRI scans. It addresses the challenge of diagnosing Alzheimer's...
Last verified:
What is Neuproscan?
NeuProScan is an innovative AI platform designed to predict the likelihood of dementia years before its onset, specifically identifying Alzheimer's disease using a single MRI scan. The tool addresses a critical gap in the current diagnostic process for Alzheimer's Disease, where diagnosis typically comes too late for most people, negatively affecting both quality and expectancy of life.
The platform helps doctors improve MRI diagnosis accuracy by reducing the high error rate in early Alzheimer's stages (29% false positives and 27% false negatives). NeuProScan is an easy-to-use, fully customizable AI platform that takes in patient MRI scans and uses a deep-learning model trained on a large repository of MRI studies to recognize complex, high-dimensional patterns associated with neurodegeneration. By evaluating imaging data at a very fine scale down to pixel-level features, it extracts biomarkers that are difficult to quantify by eye.
NeuProScan is designed for healthcare professionals looking for advanced diagnostic tools for Alzheimer's, medical institutions seeking cost-effective alternatives to PET scans, researchers and clinicians focused on early Alzheimer's intervention strategies, and families wanting early diagnosis for loved ones showing potential Alzheimer's symptoms. The system functions as a decision-support tool that complements the clinician's judgment, providing a probabilistic assessment of future cognitive decline.
Key features include advanced AI algorithms for early detection, a fully customizable platform suitable for individual doctors and hospitals, the capability to run on device or in the cloud, support for creating custom AI models, and efficient selection of relevant MRI slices for improved diagnostic precision. The output is a probabilistic assessment that clinicians can incorporate into their diagnostic workflow for risk stratification, monitoring, and earlier initiation of therapeutic or lifestyle interventions.
Neuproscan pricing
Pricing model: Free
The website does not provide specific pricing details, free tier information, or paid plan costs. NeuProScan appears to be a professional medical platform designed for healthcare institutions and doctors rather than individual consumers. Pricing information is not publicly disclosed on the website and would likely require contacting the company directly for institutional pricing.
Neuproscan pros
- Identifies Alzheimer's years ahead using a single MRI scan
- Improves MRI diagnosis accuracy by reducing false positives and negatives
- Enables early detection of Alzheimer's before clinical symptoms appear
- Facilitates more efficient use of healthcare resources
- Reduces unnecessary costly PET scans ($5000 each)
- Allows patients and families to plan for the future with certainty
- Enables participation in clinical trials for new treatments
- Uses advanced AI algorithms for early detection from MRI scans
- Fully customizable platform for individual doctors and hospitals
- Can run on device or in the cloud for operational flexibility
- Supports creation of custom AI models for specific diagnostic needs
- Efficiently selects relevant MRI slices for improved precision
- Non-invasive and requires no additional procedures for patients
- Provides quantitative, image-based risk estimate for care decisions
- Detects nuanced imaging signatures missed during conventional reads
- Enhances early identification of neurodegenerative changes before symptoms
- Complements clinician judgment with data-driven perspective
- Relies exclusively on routinely collected MRI scans
- Trained on large repository of MRI studies for accuracy
- Extracts pixel-level biomarkers difficult to quantify by eye
Neuproscan cons
- No free tier or publicly available pricing information
- Requires MRI scan input - cannot work without imaging data
- Designed for professional medical use, not consumer self-diagnosis
- May require integration with existing hospital imaging systems
- Deep learning model depends on quality of training data
- Probabilistic output requires clinical interpretation
- Custom AI model creation may require technical expertise
- Cloud deployment option may raise data privacy concerns
- Limited to Alzheimer's and dementia detection, not other conditions
Frequently asked questions about Neuproscan
What is NeuProScan?
NeuProScan is an innovative AI platform designed to predict the likelihood of dementia years before its onset. It can identify Alzheimer's disease years ahead using a single MRI scan, addressing a critical gap in the current diagnostic process for Alzheimer's Disease.
How does NeuProScan work?
NeuProScan is an easy-to-use, fully customizable AI platform that takes in patient MRI scans. It uses a deep-learning model trained on a large repository of MRI studies to recognize complex, high-dimensional patterns associated with neurodegeneration. By evaluating imaging data at a very fine scale down to pixel-level features, it extracts biomarkers that are difficult to quantify by eye and provides a probabilistic assessment of future cognitive decline.
What is the main benefit of NeuProScan?
The main benefit is that NeuProScan can identify Alzheimer's years ahead using a single MRI scan, enabling early detection before clinical symptoms appear. This gives patients and families time to plan for the future, make living arrangements, handle financial and legal matters, and establish support networks. It also enables participation in clinical trials for new drugs or therapies.
Why is an MRI predictor for Alzheimer's more than useful?
Two newly approved drugs, Lecanemab and Aducanemab, slow Alzheimer's disease progression but require a positive amyloid PET scan costing $5000. Health systems face challenges with increased PET scan demand straining resources. MRI scans are cheaper at $1300 and initially used to assess eligibility for PET scans, but MRIs have a high error rate in early Alzheimer's stages: 29% false positives and 27% false negatives. NeuProScan helps doctors improve MRI diagnosis accuracy, ensuring more effective use of costly PET scans.
Who should use NeuProScan?
NeuProScan is designed for healthcare professionals looking for advanced diagnostic tools for Alzheimer's, medical institutions seeking cost-effective alternatives to PET scans for Alzheimer's detection, researchers and clinicians focused on early Alzheimer's intervention strategies, and families wanting early diagnosis for loved ones showing potential Alzheimer's symptoms.
What are the key features of NeuProScan?
Key features include: utilizing advanced AI algorithms for early detection of Alzheimer's from MRI scans, offering a fully customizable platform suitable for both individual doctors and hospitals, capability to run on device or in the cloud for operational flexibility, supporting the creation of custom AI models to meet specific diagnostic needs, and efficiently selecting relevant slices from MRI scans for improved diagnostic precision.
How does NeuProScan help healthcare systems?
NeuProScan helps healthcare systems by improving MRI diagnosis accuracy, which ensures more effective use of costly PET scans. This reduces unnecessary PET scans, facilitating more efficient use of healthcare resources and benefiting both patients and healthcare systems by preventing strain on resources from increased PET scan demand.
Is NeuProScan invasive?
No, NeuProScan is non-invasive. It relies exclusively on routinely collected MRI scans, so it can be integrated without additional procedures for the patient. It is designed for use alongside routine imaging, highlighting subtle structural and signal changes that can escape standard visual review.
What output does NeuProScan provide?
NeuProScan provides a probabilistic assessment of future cognitive decline that clinicians can incorporate into their diagnostic workflow. It functions as a decision-support tool that complements the clinician's judgment, providing a second, data-driven perspective on the likelihood of Alzheimer's development, aiding in risk stratification, monitoring, and earlier initiation of therapeutic or lifestyle interventions.
What problem does NeuProScan address in Alzheimer's diagnosis?
NeuProScan addresses the critical problem that Alzheimer's diagnosis comes too late for most people, affecting both quality and expectancy of life. It addresses the critical gap in the current diagnostic process where MRI scans have high error rates in early Alzheimer's stages (29% false positives and 27% false negatives), making it difficult to assess eligibility for expensive PET scans needed for new treatment drugs.